QUIT
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -0.11 | $0 | -$8M |
| 2026 Q2 | -0.80 | $0 | -$11M |
| 2026 Q1 | -0.19 | $0 | -$7M |
| 2025 Q4 | -0.28 | $0 | -$18M |
| 2025 Q3 | -0.28 | $0 | -$11M |
| 2025 Q2 | -0.37 | $0 | -$9M |
| 2025 Q1 | -0.37 | $0 | -$11M |
| 2024 Q4 | -0.36 | $0 | -$9M |